Royalty Pharma Overview
- Founded
- 1996

- Status
- Public
- Employees
- 66

- Stock Symbol
- RPRX

- Investments
- 39
- Share Price
- $39.52
- (As of Friday Closing)
Royalty Pharma General Information
Description
Royalty Pharma PLC is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company assembles a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's therapies, which includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Johnson & Johnson's Tremfya, Gilead's Trodelvy, Merck's Januvia, Novartis' Promacta, Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Contact Information
- 110 East 59th Street
- Floor 33
- New York, NY 10022
- United States
Royalty Pharma Timeline
Royalty Pharma Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$39.52 | $39.78 | $34.86 - $47.10 | $17.4B | 435M | 2.1M | $1.44 |
Royalty Pharma Financials Summary
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 25,700,880 | 26,106,932 | 27,852,217 | |
Revenue | 2,278,485 | 2,289,463 | 2,122,353 | 1,814,254 |
EBITDA | 1,362,624 | 1,376,804 | 1,853,692 | 2,731,587 |
Net Income | 602,370 | 619,728 | 975,040 | 2,348,535 |
Total Assets | 17,378,888 | 17,515,865 | 16,020,286 | 12,449,895 |
Total Debt | 7,101,138 | 7,096,070 | 5,816,584 | 6,238,122 |
Royalty Pharma Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.
Request a free trialRoyalty Pharma Comparisons
Industry
00000 &
000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialRoyalty Pharma Competitors (2)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Merck & Co. | Corporation | Kenilworth, NJ | 00000 | 00000000 | ||
000000 | Corporation | New York, NY | 00000 | 000000000-00 |
Royalty Pharma Patents
Royalty Pharma Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
FR-3056234-B1 | Rolling gear and / or person access control device to a predetermined zone | Active | 20-Sep-2016 | 0000000000 | |
FR-3056234-A1 | Device for controlling the access to the rolling machine and / or person to a predetermined zone | Granted | 20-Sep-2016 | 0000000000 | 0 |
FR-3056235-A1 | Device for controlling the access to the rolling machine and / or person to a predetermined zone | Pending | 20-Sep-2016 | 0000000000 | |
EP-3516120-B1 | Device for controlling access of a wheeled vehicle and/or person to a predetermined area | Active | 20-Sep-2016 | 0000000000 | |
EP-3516120-A1 | Device for controlling access of a wheeled vehicle and/or person to a predetermined area | Granted | 20-Sep-2016 | E01F13/044 |
Royalty Pharma Executive Team (16)
Royalty Pharma Board Members (13)
Name | Representing | Role | Since |
---|---|---|---|
000000000 000000000 | Royalty Pharma | Board Member | 000 0000 |
00000000000 0000 | Self | Executive Vice President & Vice Chairman | 000 0000 |
00000 0000000 | Self | Board Member | 000 0000 |
00000 00 00000 00.0 | Self | Board Member | 000 0000 |
0000000 000000 | Self | Board Member | 000 0000 |
Royalty Pharma Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialRoyalty Pharma Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.
Request a free trialRoyalty Pharma Investments & Acquisitions (39)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 | 02-May-2022 | 00000 0000 | 00000 | Drug Delivery | |
000000000000 | 07-Jan-2022 | 0000 | Pharmaceuticals | ||
00000000 0000 | 22-Nov-2021 | 0000 | 0000 | Pharmaceuticals | 00000 000 |
0000000000000 | 01-Apr-2021 | 000000000 | 00000 | Other Healthcare Services | 00000 000 |
Biohaven Pharmaceutical | 07-Aug-2020 | PIPE | 00000 | Drug Discovery |
Royalty Pharma Subsidiaries (1)
Company Name | Industry | Location | Founded |
---|---|---|---|
0000000 | Pharmaceuticals |
Royalty Pharma Exits (3)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
00000000 000000000 | 07-Aug-2020 | 0000 | 00000 | Completed |
|
00000000 000000000 | 19-Jun-2018 | 0000 | 0000 | Completed |
|
Cypress Bioscience | 15-Dec-2010 | Buyout/LBO | 00000 | Completed |
|